Drug utilization study and safety evaluation based on prediction approach for drug interactions in chemotherapy
| Project/Area Number |
22790511
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2010: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 医薬品副作用・相互作用 / がん化学療法 / 漢方薬 / 安全性 |
|---|
| Research Abstract |
The aim of this study was to describe utilization of anticancer drugs and concomitant medicines including Kanpo medicines, and evaluate safety of concomitant Kampo medicines in chemotherapy. As a result, Co-administration of Daikenchuto or Hangeshashinto, in patients treated with paclitaxel or irinotecan, respectively, showed significant association with decrease of platelet count over grade 3 based on Common Terminology Criteria for Adverse Events v4. 0 criteria. In addition, some of co-administrated Kampo medicines could affect occurrence of adverse effects, such as myelosuppression, electrolyte abnormality, or hepatic dysfunction.
|
Report
(3 results)
Research Products
(1 results)
